| International scoring system for evaluating prognosis in myelodysplastic syndromes P Greenberg, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, M Sanz, ... Blood, The Journal of the American Society of Hematology 89 (6), 2079-2088, 1997 | 5564 | 1997 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 3004 | 2009 |
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, ... Journal of clinical oncology 28 (4), 562-569, 2010 | 1164 | 2010 |
| ‘Off-the-shelf’allogeneic CAR T cells: development and challenges S Depil, P Duchateau, SA Grupp, G Mufti, L Poirot Nature reviews Drug discovery 19 (3), 185-199, 2020 | 864 | 2020 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ... Blood, The Journal of the American Society of Hematology 122 (17), 2943-2964, 2013 | 800 | 2013 |
| Guidelines for the diagnosis and management of adult aplastic anaemia. SB Killick, N Bown, J Cavenagh, I Dokal, T Foukaneli, A Hill, P Hillmen, ... British journal of haematology 172 (2), 2016 | 777 | 2016 |
| Myelodysplastic syndromes: a scoring system with prognostic significance GJ Mufti, JR Stevens, DG Oscier, TJ Hamblin, D Machin British journal of haematology 59 (3), 425-433, 1985 | 669 | 1985 |
| A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ... Blood, The Journal of the American Society of Hematology 118 (14), 3765-3776, 2011 | 566 | 2011 |
| TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression M Jädersten, L Saft, A Smith, A Kulasekararaj, S Pomplun, G Göhring, ... Journal of clinical oncology 29 (15), 1971-1979, 2011 | 566 | 2011 |
| The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS JE Parker, GJ Mufti, F Rasool, A Mijovic, S Devereux, A Pagliuca Blood, The Journal of the American Society of Hematology 96 (12), 3932-3938, 2000 | 483 | 2000 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 470 | 2020 |
| Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical … R Martino, S Iacobelli, R Brand, T Jansen, A van Biezen, J Finke, ... Blood 108 (3), 836-846, 2006 | 434 | 2006 |
| Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. D Bowen, D Culligan, S Jowitt, S Kelsey, G Mufti, D Oscier, J Parker British journal of haematology 120 (2), 2003 | 433 | 2003 |
| Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the … GJ Mufti, JM Bennett, J Goasguen, BJ Bain, I Baumann, R Brunning, ... haematologica 93 (11), 1712-1717, 2008 | 410 | 2008 |
| Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin JW Janssen, M Buschle, M Layton, HG Drexler, J Lyons, ... | 405 | 1989 |
| Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel T De Witte, D Bowen, M Robin, L Malcovati, D Niederwieser, ... Blood, The Journal of the American Society of Hematology 129 (13), 1753-1762, 2017 | 377 | 2017 |
| Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia ZY Lim, R Brand, R Martino, A van Biezen, J Finke, A Bacigalupo, ... Journal of Clinical Oncology 28 (3), 405-411, 2010 | 360 | 2010 |
| Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells A Essafi, S Fernández de Mattos, YAM Hassen, I Soeiro, GJ Mufti, ... Oncogene 24 (14), 2317-2329, 2005 | 352 | 2005 |
| Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia … J Donadieu, T Leblanc, BB Meunier, M Barkaoui, O Fenneteau, ... haematologica 90 (1), 45-53, 2005 | 347 | 2005 |
| Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd–Chiari syndrome RK Patel, NC Lea, MA Heneghan, NB Westwood, D Milojkovic, ... Gastroenterology 130 (7), 2031-2038, 2006 | 337 | 2006 |
